Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

Ileostomy - Stoma Clinical Trial

Official title:

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03953170
• Other study ID #: Teduglutide
• Status: Withdrawn
• Phase: Phase 3
• Start date: June 2, 2022
• Est. completion date: December 29, 2022

Study information

• Verified date: February 2023
• Source: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to investigate the natural history of patients with a temporary ileostomy and to assess the effect of Teduglutide in reducing morbidity, hospital readmissions and post reversal complications.

Description:

This is a prospective, controlled, randomized, double blind study. A total of 36 subjects will be enrolled into the study. Subjects will be randomized to receive Teduglutide or Placebo for 12 weeks or until the ileostomy is reversed. Teduglutide or placebo will be administered via a daily subcutaneous injection into the abdomen or thigh. The sites will be rotated with each injection. If adverse effects develop the subjects will be permitted to hold drug administration for a maximum of 5 days in total during the 12-week study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 29, 2022
• Est. primary completion date: November 25, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients who are undergoing temporary ileostomy (loop or end ileostomy) regardless of the indication or technique used (open or laparoscopy) as part of their regular standard of care
• Age- 18-80 years old
• Normal routine laboratories (CMP, CBC, CRP, amylase, lipase)
• Permitted medications will include biologicals which dose has not been changed for > 6 months, and immunosuppressant therapy which dose has not been changed for 3 months (i.e. codeine sulfate, loperamide, or Lomotil)

Exclusion Criteria:

• Emergency need for ileostomy
• Pregnant or nursing
• Malnutrition or requiring parenteral or enteral nutrition
• Known intestinal obstruction, stricture, or adhesions that would predispose the patient to the development of intestinal obstruction, perforation, hemorrhage, or intestinal abscess
• Intestinal fistulas or abscess proximal to the ostomy
• Small bowel resection greater than 50 cm.
• Clinically significant cardiovascular, renal, pulmonary, endocrine, immunologic, dermatology, neurological or psychiatric disorders
• Cholelithiasis or pancreatitis
• Family history of colorectal cancer or familial polyposis
• Cancer in the last 5 years
• History of HIV, Hepatitis B or C, or other acute systemic or intestinal infections requiring antibiotics
• Use of GLP1 analogues which may increase the risk of acute pancreatitis
• Treatment of Octreotide

Related Conditions & MeSH terms

• Ileostomy - Stoma

Intervention

Drug:
• Teduglutide
Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only. The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA.
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Shire

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in daily 24 hr ileostomy collection	(mL/day)	Change from time of surgery to 12 weeks